LIFECORE BIOMEDICAL, INC. DE (LFCR): Nasdaq/NYSE listing notice — Lifecore receives Nasdaq notice for delayed Q3 10-Q; hearing held April 16, decision pending

LIFECORE BIOMEDICAL, INC. DE

Nasdaq notice on April 15, 2024, cites continued non-compliance with Listing Rule 5250(c)(1) due to late Q3 10-Q and prior Q1/Q2 filings.
Company appealed prior Staff Delisting Determination; hearing held April 16, 2024, requesting further stay of suspension/delisting.
Nasdaq Hearings Panel has not yet issued a decision; no immediate effect on LFCR stock trading.
Company intends to file overdue reports as promptly as possible but gives no assurance of timeline or panel grant.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

LIFECORE BIOMEDICAL, INC. DE received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 5250(c)(1)

Exact text from the filing

and November 29, 2023 (the “Q1 Form 10-Q” and “Q2 Form 10-Q,” respectively, and together with the Q3 Form 10-Q, the “Filings”) with the Securities and Exchange Commission (the “SEC”), the Company continues not to be in compliance with the requirements for continued listing under Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), and that the Nasdaq Hearings Panel would consider the delinquency in the filing of the Q3 Form 10-Q in rendering its determination regarding the Company’s continued listing on Nasdaq Global Select Market . The Notice has no immediate effect on the listing or trading

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LIFECORE BIOMEDICAL, INC. DE filing history →

Source: SEC EDGAR

accession 0001005286-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.